PCV21 + 20vPCV
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Jan 20, 2026 → Jan 7, 2027
NCT ID
NCT07247188About PCV21 + 20vPCV
PCV21 + 20vPCV is a phase 3 stage product being developed by Sanofi for Sickle Cell Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07247188. Target conditions include Sickle Cell Disease.
What happened to similar drugs?
3 of 20 similar drugs in Sickle Cell Disease were approved
Approved (3) Terminated (10) Active (8)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07247188 | Phase 3 | Recruiting |
| NCT06838000 | Phase 3 | Active |
Competing Products
20 competing products in Sickle Cell Disease